A Rapid Fluorescence Assay for Sphingosine-1-phosphate Lyase Enzyme Activity
Overview
Affiliations
Sphingosine-1-phosphate (S1P) lyase (SPL) catalyzes the conversion of S1P to ethanolamine phosphate and hexadecenal. This enzyme plays diverse roles in physiology and disease and, thus, may be useful as a disease marker and/or drug target. Unfortunately, the radioisotope-based assay currently used to quantify SPL activity is suboptimal. We have devised an assay using a commercially available omega(7-nitro-2-1,3-benzoxadiazol-4-yl)-d-erythro (NBD)-labeled fluorescent substrate. Alternatively, we provide a method for synthesis of the substrate from NBD-sphingosine. Enzyme activity is determined by following the formation of NBD-aldehyde product, which is isolated from unreacted substrate by lipid extraction and quantified after separation by HPLC using a C18 column. A fluorescent NBD-C18-sphingosine internal standard is used to control for extraction efficiency. The reaction is linear over 20 min and total protein concentrations of 20-200 mg/l. The sensitivity of the fluorescence assay is comparable to or better than that of the radioactive assay, and SPL levels as low as 8 pmol/mg/min were readily detected. Semicarbazide, a nonspecific SPL inhibitor, reduced SPL activity in vitro by approximately 70% using both standard and fluorescence methods. Product inhibition was not observed using ethanolamine phosphate and a commercially available source of hexadecenal. This method is suitable for quantifying SPL activity in a variety of cell and tissue sources.
Cellini B, Pampalone G, Camaioni E, Pariano M, Catalano F, Zelante T Sci Rep. 2023; 13(1):22692.
PMID: 38123809 PMC: 10733307. DOI: 10.1038/s41598-023-50121-4.
Sphingosine 1-Phosphate Lyase in the Developing and Injured Nervous System: a Dichotomy?.
Xiao J Mol Neurobiol. 2023; 60(12):6869-6882.
PMID: 37507574 PMC: 10657793. DOI: 10.1007/s12035-023-03524-3.
Sah R, Anand S, Dar W, Jain R, Kumari G, Madan E Microbiol Spectr. 2023; :e0276622.
PMID: 36744922 PMC: 10100792. DOI: 10.1128/spectrum.02766-22.
Compartmentalization of Sphingolipid metabolism: Implications for signaling and therapy.
Canals D, Clarke C Pharmacol Ther. 2021; 232:108005.
PMID: 34582834 PMC: 9619385. DOI: 10.1016/j.pharmthera.2021.108005.
Lysophospholipids in Lung Inflammatory Diseases.
Zhao J, Zhao Y Adv Exp Med Biol. 2021; 1303:373-391.
PMID: 33788203 PMC: 8919210. DOI: 10.1007/978-3-030-63046-1_20.